

# LAIS

## Loberamisal for Acute Ischaemic Stroke

**OBJECTIVE:** To evaluate the safety and efficacy of loberamisal in treating acute ischemic stroke (AIS) compared to placebo in adults with moderate to moderate-severe NIH stroke scale (NIHSS score 7-20)

**STUDY DESIGN:** International (32 sites in China), randomized, double-blind, parallel, placebo-controlled, phase 2 trial, N=998

**CONCLUSIONS:** When administered within 48 hours of AIS, loberamisal was associated with a 13% absolute increase in the proportion of adults achieving excellent functional outcomes at 90 days, with a favorable safety profile, compared to placebo.



American  
Heart  
Association.